Login

Healthcare

00:10:00
BioInvent CEO Explores Portfolio Strategy and Upcoming Breakthroughs | Dr. Martin Welschof, CEO , BioInvent International AB.
00:10:00
Thomas Olin, CEO of Kancera AB, Discusses Strategic Advances in Biopharma Innovation | Dr. Thomas Olin, CEO , Kancera AB.
00:10:00
Leading the Charge in the Psychedelic Movement with Filament Health | Benjamin Lightburn, CEO , Filament Health Corp.
00:10:00
CEO Thomas Olin on Innovation and Biopharma Advances | Dr. Thomas Olin, CEO , Kancera AB.
00:10:00
Filament Health Partners with Entheotech in Exclusive Licensing and Co-Development Agreement | Benjamin Lightburn, CEO , Filament Health Corp.
00:10:00
Filament Health and Reset Pharmaceuticals Strike Licensing Deal for Psilocybin Drug PEX010 | Benjamin Lightburn, CEO , Filament Health Corp.
00:10:00
Pioneering Drug Development for Inflammation and Cancer | Dr. Thomas Olin, CEO , Kancera AB.
00:10:00
BioInvent CEO Highlights Major Milestone and Future Goals | Dr. Martin Welschof, CEO , BioInvent International AB.
00:10:00
CEO Ben Lightburn Discusses Advancing Psychedelic Medicine through Natural Extraction | Benjamin Lightburn, CEO , Filament Health Corp.
00:10:00
Thomas Olin Highlights Kancera’s Latest Advances and Strategic Focus | Dr. Thomas Olin, CEO , Kancera AB.
00:10:00
Revolutionizing Healing with Naturally Derived Psychedelics | Benjamin Lightburn, CEO , Filament Health Corp.

© 2017 - Neuhu+